News

4th China Government Procurement: up to 95% reduction on drugs

4th China Government Procurement: up to 95% reduction in drugs. The fourth batch of national sourcing price lists, the biggest drop is 95%+! This round of centralized procurement included a total of 45 varieties and 80 specifications, including 8 injection varieties, 3 eye drops, and the rest are oral preparations.

Today (February 3), the fourth batch of national centralized procurement officially opened bids. This round of centralized procurement included a total of 45 varieties and 80 specifications, including 8 injections, 3 eye drops, and the rest are oral preparations. According to the analysis, a total of 151 enterprises are eligible for the application, involving 23 foreign-funded enterprises and 128 domestic enterprises, among which there are more than 5 competing enterprises in 16 varieties, showing a relatively fierce competition.

Chinese domestic companies are the main suppliers

This time, the top three products held by local companies are Yangzijiang Pharmaceutical, Qilu Pharmaceutical, and Fosun Pharma.

Among them, Yangtze River is propofol medium/long chain fat emulsion injection, doxofylline injection, loratadine tablets, ticagrelor tablets, cefprozil tablets, hyaluronic acid (sodium hyaluronate) eye drops Drugs, parecoxib sodium for injection, levofloxacin tablets, pantoprazole sodium for injection.

Qilu Pharmaceutical has 7 varieties in the market, amisulpride tablets, pregabalin capsules, pramipexole hydrochloride tablets, terbinafine hydrochloride tablets, bivarudine for injection, bortezomib for injection, and Pare for injection Coxib sodium.

Among them, Chia Tai Tianqing offered parecoxib sodium injection with a decrease of 91.9%. It is reported that a total of 16 pharmaceutical companies participated in the competition for this product. It is one of the injection products that have passed the most consistent evaluation so far. , The decline is about 90%.

Kelun Pharmaceutical’s Engligliflozin tablets, propofol medium/long-chain fat emulsion injection, ambroxol hydrochloride injection, and parecoxib sodium for injection were all selected for this national centralized procurement.

Up to 95% reduction in drugs

In this centralized procurement, many domestic companies are still actively reducing prices. Some popular products such as ambroxol hydrochloride injection, Kelun Pharmaceutical and Sichuan Meidakang Huakang have dropped to 0.338 yuan and 0.366 yuan each.

Jiangxi Shanxiang Pharmaceutical’s Esomeprazole Magnesium Enteric-coated Tablets and Sorafenib Tosylate were both shortlisted. Sorafenib was quoted at 24.48 yuan per tablet, which was nearly a quarter of the original Bayer price. Sorafenib is a multi-kinase inhibitor developed by Bayer and is mainly used clinically to treat hepatocellular carcinoma, renal cell carcinoma and thyroid cancer.

Emeishan Tonghui’s postoperative pain medication injection parecoxib sodium dropped to 2.98 yuan per bottle, far below the limit price of 55.2353 yuan, a drop of nearly 95%. The original research Pfizer failed the bid at a price close to 100 yuan per bottle. In addition, like the commonly used ophthalmic drug hyaluronic acid (sodium hyaluronate) eye drops, Zhenshiming dropped from 27.5 yuan to 5.8 yuan, a decrease of 75%.

It is worth mentioning that on the day before the collection (February 2), 4 varieties were thrilled to catch the last train, namely: Chia Tai Tianqing’s Esomeprazole Magnesium Enteric-coated Capsules (quotation 2.91 yuan) ), Engeliejing tablets (price 1.85 yuan) passed the consistency evaluation, it is the shortest variety from the consistency evaluation to the collection.

China Government Procurement: up to 95% reduction on drugs